Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept.
A case of recurrent Mycobacterium xenopi infection presenting as Pott's disease in a patient receiving etanercept for severe rheumatoid arthritis is described. A 49-y-old Caucasian male had received a total of 11 months of anti-mycobacterial therapy for hip infection acquired 15 months earlier; he presented with progressive back pain, which was diagnosed as Pott's disease. He had been treated with etanercept in addition to his prior immunosuppressive agents after the diagnosis of hip infection.
Yim
Kyongwook
K
Division of Infectious Diseases, Department of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
Nazeer
Syed H
SH
Kiska
Deanna
D
Rose
Frederick B
FB
Brown
Douglas
D
Cynamon
Michael H
MH
D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D004269:DNA, Bacterial / Q000032:analysis; D000068800:Etanercept; D005500:Follow-Up Studies; D006622:Hip Prosthesis / Q000009:adverse effects; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009165:Mycobacterium Infections, Nontuberculous / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D019912:Mycobacterium xenopi / Q000302:isolation & purification*; D012150:Polymorphism, Restriction Fragment Length; D016459:Prosthesis-Related Infections / Q000175:diagnosis / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D004269:DNA, Bacterial; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept